@saymaa_91's 10-kilo Wegovy claim, fact-checked
Quick answer
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics hormones controlling blood sugar and appetite. Clinical trials show average weight loss of 14.9% over 68 weeks at the 2.4mg maintenance dose, though individual results vary significantly.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
Swiss influencer @saymaa_91 posted a TikTok claiming she lost 10 kilos (22 pounds) on Wegovy, a semaglutide injection approved for weight management. The video has racked up nearly 11,000 views, but provides zero context about timeframe, side effects, or medical supervision.
What does this video actually claim?
The creator states she lost 10 kilos using Wegovy, hashtagging it as a weight loss success story from Switzerland. That's about it. No mention of how long this took, what dose she used, or whether she experienced any side effects.
The lack of detail is telling. Real weight loss with semaglutide doesn't happen overnight, and the medication comes with a substantial side effect profile that most users can't ignore. Her presentation makes it sound almost effortless.
The video essentially functions as a before-and-after testimonial without the medical context that would help viewers understand what Wegovy actually involves.
Is a 10-kilo loss realistic on Wegovy?
Yes, but it depends entirely on her starting weight and treatment duration. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% of their body weight after 68 weeks on 2.4mg semaglutide.
If @saymaa_91 started at 80 kilos, a 10-kilo loss would represent 12.5% weight reduction, which falls within the expected range. But if she weighed 60 kilos initially, that same 10-kilo loss would be 16.7%, which is above average.
The STEP trials showed most weight loss occurred in the first 20 weeks, plateauing afterward. Without knowing her timeline, it's impossible to verify if her results align with clinical data.
What's missing from this success story?
The video completely ignores Wegovy's side effect profile, which affects nearly everyone who takes it. In STEP 1, 74% of participants experienced gastrointestinal side effects including nausea, vomiting, and diarrhea.
She also doesn't mention the medication's cost, which runs about $1,300 monthly in the US (Swiss pricing varies). Most people can't just casually try Wegovy like she implies.
The biggest omission is medical supervision. Wegovy requires careful dose escalation over 16-20 weeks, starting at 0.25mg weekly and increasing gradually to prevent severe nausea. You can't just start taking it and expect smooth sailing.
What should you actually know about Wegovy?
Semaglutide works by mimicking GLP-1, a hormone that slows digestion and signals fullness to your brain. It's not a quick fix or lifestyle hack, it's a prescription medication for people with obesity or overweight with complications.
The weight loss is real, but it requires ongoing treatment. STEP 1 showed that people who stopped semaglutide regained most of the weight within a year. You're essentially committing to long-term therapy.
Swiss regulations require medical oversight for Wegovy prescriptions, so @saymaa_91 presumably had proper monitoring. But her casual presentation doesn't reflect the medical complexity involved in safe semaglutide treatment.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @saymaa_91's 10-kilo Wegovy claim, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics hormones controlling blood sugar and appetite.
FormBlends verdict
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics hormones controlling blood sugar and appetite. Clinical trials show average weight loss of 14.9% over 68 weeks at the 2.4mg maintenance dose, though individual results vary significantly.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics hormones controlling blood sugar and appetite. Clinical trials show average weight loss of 14.9% over 68 weeks at the 2.4mg maintenance dose, though individual results vary significantly.
- Wegovy (semaglutide) produced 14.9% average weight loss in the 68-week STEP 1 trial, making 10-kilo losses plausible depending on starting weight
- 74% of STEP 1 participants experienced gastrointestinal side effects including nausea, vomiting, and diarrhea
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Wegovy (semaglutide) produced 14.9% average weight loss in the 68-week STEP 1 trial, making 10-kilo losses plausible depending on starting weight
- 74% of STEP 1 participants experienced gastrointestinal side effects including nausea, vomiting, and diarrhea
- Treatment requires 16-20 week dose escalation starting at 0.25mg weekly, increasing gradually to 2.4mg maintenance dose
- Weight regain occurs when treatment stops, with patients regaining most lost weight within a year according to follow-up studies
- Wegovy costs approximately $1,300 monthly in the US and requires ongoing medical supervision in most countries including Switzerland
- The medication is approved for people with BMI ≥30 or BMI ≥27 with weight-related health complications, not general weight management
- Individual results vary significantly, and the drug doesn't work equally well for everyone despite clinical trial averages
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
🇨🇭 Influleleuse 🇨🇭 · TikTok creator
10.9K views on this video
10 kilos en moins 👑#wegovy #suisse #tiktoksuisse🇨🇭 #pertedepoids
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by 🇨🇭 Influleleuse 🇨🇭, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.